Array Biopharma Inc (ARRY) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its stake in Array Biopharma Inc (NASDAQ:ARRY) by 81.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,033,000 shares of the biopharmaceutical company’s stock after buying an additional 465,000 shares during the period. Handelsbanken Fonder AB’s holdings in Array Biopharma were worth $13,222,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Array Biopharma by 12.6% in the fourth quarter. BlackRock Inc. now owns 15,252,802 shares of the biopharmaceutical company’s stock worth $195,236,000 after buying an additional 1,707,369 shares during the period. Franklin Resources Inc. lifted its holdings in Array Biopharma by 12.0% in the fourth quarter. Franklin Resources Inc. now owns 9,169,836 shares of the biopharmaceutical company’s stock worth $117,374,000 after buying an additional 979,072 shares during the period. Point72 Asset Management L.P. lifted its holdings in Array Biopharma by 274.4% in the third quarter. Point72 Asset Management L.P. now owns 9,008,999 shares of the biopharmaceutical company’s stock worth $110,811,000 after buying an additional 6,602,999 shares during the period. BVF Inc. IL lifted its holdings in Array Biopharma by 35.7% in the fourth quarter. BVF Inc. IL now owns 8,686,498 shares of the biopharmaceutical company’s stock worth $111,187,000 after buying an additional 2,283,973 shares during the period. Finally, Driehaus Capital Management LLC lifted its holdings in Array Biopharma by 19.8% in the fourth quarter. Driehaus Capital Management LLC now owns 2,513,682 shares of the biopharmaceutical company’s stock worth $32,175,000 after buying an additional 416,277 shares during the period. Institutional investors and hedge funds own 96.41% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several analysts have commented on ARRY shares. Leerink Swann upgraded shares of Array Biopharma from a “market perform” rating to an “outperform” rating in a report on Monday, January 22nd. BidaskClub lowered shares of Array Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday. SunTrust Banks reiterated a “buy” rating and set a $20.00 target price on shares of Array Biopharma in a report on Tuesday, February 6th. Jefferies Group lifted their target price on shares of Array Biopharma to $13.00 and gave the company a “buy” rating in a report on Friday, December 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Array Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Monday, January 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $16.43.

Array Biopharma Inc (NASDAQ:ARRY) opened at $16.35 on Friday. Array Biopharma Inc has a 1-year low of $6.73 and a 1-year high of $18.78. The stock has a market cap of $3,488.30, a P/E ratio of -21.23 and a beta of 1.80. The company has a current ratio of 6.17, a quick ratio of 6.17 and a debt-to-equity ratio of 0.39.

Array Biopharma (NASDAQ:ARRY) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Array Biopharma had a negative net margin of 98.51% and a negative return on equity of 107.79%. The firm had revenue of $42.21 million during the quarter, compared to analyst estimates of $26.81 million. During the same period last year, the business earned ($0.14) earnings per share. The business’s revenue was down 5.2% on a year-over-year basis. sell-side analysts predict that Array Biopharma Inc will post -0.88 EPS for the current fiscal year.

In related news, CFO Jason Haddock sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $13.73, for a total transaction of $102,975.00. Following the completion of the sale, the chief financial officer now owns 36,368 shares of the company’s stock, valued at $499,332.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Charles M. Baum sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $16.90, for a total transaction of $845,000.00. Following the sale, the director now directly owns 35,000 shares of the company’s stock, valued at approximately $591,500. The disclosure for this sale can be found here. Insiders have sold 278,016 shares of company stock valued at $4,718,508 in the last three months. 3.18% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3293864/array-biopharma-inc-arry-shares-bought-by-handelsbanken-fonder-ab.html.

About Array Biopharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Want to see what other hedge funds are holding ARRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Array Biopharma Inc (NASDAQ:ARRY).

Institutional Ownership by Quarter for Array Biopharma (NASDAQ:ARRY)

Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.49 EPS Expected for CBRE Group  This Quarter
$0.49 EPS Expected for CBRE Group This Quarter
Zacks: Brokerages Anticipate Hudson  Will Announce Earnings of $0.03 Per Share
Zacks: Brokerages Anticipate Hudson Will Announce Earnings of $0.03 Per Share
Extended Stay America  Stock Rating Reaffirmed by Robert W. Baird
Extended Stay America Stock Rating Reaffirmed by Robert W. Baird
Zacks Investment Research Downgrades Incyte  to Hold
Zacks Investment Research Downgrades Incyte to Hold
Zacks Investment Research Downgrades Tata Motors  to Sell
Zacks Investment Research Downgrades Tata Motors to Sell
RBB Bancorp  to Issue Quarterly Dividend of $0.09
RBB Bancorp to Issue Quarterly Dividend of $0.09


© 2006-2018 Ticker Report. Google+.